Sai Parenteral's (NSE:SAIPARENT) Marketable Securities: ₹84 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Marketable Securities?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Marketable Securities is ₹84 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sai Parenteral's's Marketable Securities for the quarter that ended in Sep. 2025 was ₹84 Mil.

Sai Parenteral's's annual Marketable Securities stayed the same from Mar. 2023 (₹0 Mil) to Mar. 2024 (₹0 Mil) but then increased from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹69 Mil).

Sai Parenteral's  (NSE:SAIPARENT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sai Parenteral's Marketable Securities Related Terms

Sai Parenteral's Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Marketable Securities Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Marketable Securities
0.00 0.00 68.74

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Marketable Securities 0.00 0.00 68.74 83.58
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ₹84 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Marketable Securities of ₹84 Mil as of Sep. 2025. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Marketable Securities too high?
Sai Parenteral's' current Marketable Securities is ₹84 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Marketable Securities compare to LLY and JNJ?
Sai Parenteral's' Marketable Securities of ₹84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Marketable Securities is ₹84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Marketable Securities of ₹84 Mil. The current Marketable Securities is ₹84 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Marketable Securities is ₹84 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price